Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;51(11):1812-1817.
doi: 10.1016/j.jpedsurg.2016.07.015. Epub 2016 Aug 5.

Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients

Affiliations

Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients

Sajid A Khan et al. J Pediatr Surg. 2016 Nov.

Abstract

Introduction: Colorectal cancer (CRC) diagnosed before age 30 years is a fatal disease whose biology remains poorly understood. To understand its pathogenesis, we compared molecular and clinical data in surgically treated early-age onset and adult onset patients.

Materials and methods: Clinical data and tumor tissue were collected retrospectively for 94 patients with early-age onset CRC (age ≤30 years) and compared to 275 adult CRC patients (age ≥50 years). Tumor morphology, microsatellite instability (MSI) and stability (MSS), KRAS and BRAF mutations, and mismatch repair (MMR) expression (MSH2, MLH1, MSH6, PMS2) were assessed.

Results: Early-age CRC was distinguished from adult CRC by advanced stage presentation (P<0.001), frequent high grade cancers (P<0.001), and poor prognosis (P<0.001). MSI was associated with favorable survival and MMR loss in both groups. Compared to adults, MSI in early-onset CRC was more prevalent (P<0.01), not tightly linked to MLH1/PMS2 loss, and never associated with BRAFV600E mutations (P<0.01). MSS/BRAFV600E genotype had poor prognosis and was more prevalent in early-age CRC (9% vs. 3%).

Discussion: Specific genetic subtypes are found at different frequencies in early-age onset and adult onset CRC. Complete absence of the indolent MSI/BRAFV600E genotype and enrichment in the unfavorable MSS/BRAFV600E genotype help explain the poor prognosis of early onset CRC.

Keywords: BRAF; Early onset colorectal cancer; MSI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Disease-specific survival according to age, microsatellite genotype and microsatellite genotype in relation to BRAF mutational status. a. Disease-specific survival of early-age onset colorectal cancer compared to adult onset colorectal cancer patients. 5-year disease-specific survival in the early-age onset group is worse compared to the adult onset group (48% vs. 78%, P<0.001). b. Disease-specific survival in adult-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (93% vs. 73%, P=0.006). c. Disease-specific survival in early-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (65% vs. 39%, P=0.048). d. Disease-specific survival in early-age onset group with microsatellite stability (MSS) phenotype stratified according to BRAF mutational status. 5-year disease-specific survival trended worse in patients possessing the MSS/BRAFV600Emut genotype compared to the MSS/BRAF wild-type (WT) genotype (16% vs. 42%, p=0.23). e. Disease-specific survival of adult onset-MSI genotype compared to early-age onset-MSI genotype in colorectal cancer patients. Both adult and early-age onset MSI were associated with favorable survivals, though adult-MSI genotype was associated with a more favorable 5-year disease-specific survival (93% vs. 65%, P=0.01).
Figure 1
Figure 1
Disease-specific survival according to age, microsatellite genotype and microsatellite genotype in relation to BRAF mutational status. a. Disease-specific survival of early-age onset colorectal cancer compared to adult onset colorectal cancer patients. 5-year disease-specific survival in the early-age onset group is worse compared to the adult onset group (48% vs. 78%, P<0.001). b. Disease-specific survival in adult-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (93% vs. 73%, P=0.006). c. Disease-specific survival in early-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (65% vs. 39%, P=0.048). d. Disease-specific survival in early-age onset group with microsatellite stability (MSS) phenotype stratified according to BRAF mutational status. 5-year disease-specific survival trended worse in patients possessing the MSS/BRAFV600Emut genotype compared to the MSS/BRAF wild-type (WT) genotype (16% vs. 42%, p=0.23). e. Disease-specific survival of adult onset-MSI genotype compared to early-age onset-MSI genotype in colorectal cancer patients. Both adult and early-age onset MSI were associated with favorable survivals, though adult-MSI genotype was associated with a more favorable 5-year disease-specific survival (93% vs. 65%, P=0.01).
Figure 1
Figure 1
Disease-specific survival according to age, microsatellite genotype and microsatellite genotype in relation to BRAF mutational status. a. Disease-specific survival of early-age onset colorectal cancer compared to adult onset colorectal cancer patients. 5-year disease-specific survival in the early-age onset group is worse compared to the adult onset group (48% vs. 78%, P<0.001). b. Disease-specific survival in adult-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (93% vs. 73%, P=0.006). c. Disease-specific survival in early-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (65% vs. 39%, P=0.048). d. Disease-specific survival in early-age onset group with microsatellite stability (MSS) phenotype stratified according to BRAF mutational status. 5-year disease-specific survival trended worse in patients possessing the MSS/BRAFV600Emut genotype compared to the MSS/BRAF wild-type (WT) genotype (16% vs. 42%, p=0.23). e. Disease-specific survival of adult onset-MSI genotype compared to early-age onset-MSI genotype in colorectal cancer patients. Both adult and early-age onset MSI were associated with favorable survivals, though adult-MSI genotype was associated with a more favorable 5-year disease-specific survival (93% vs. 65%, P=0.01).
Figure 1
Figure 1
Disease-specific survival according to age, microsatellite genotype and microsatellite genotype in relation to BRAF mutational status. a. Disease-specific survival of early-age onset colorectal cancer compared to adult onset colorectal cancer patients. 5-year disease-specific survival in the early-age onset group is worse compared to the adult onset group (48% vs. 78%, P<0.001). b. Disease-specific survival in adult-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (93% vs. 73%, P=0.006). c. Disease-specific survival in early-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (65% vs. 39%, P=0.048). d. Disease-specific survival in early-age onset group with microsatellite stability (MSS) phenotype stratified according to BRAF mutational status. 5-year disease-specific survival trended worse in patients possessing the MSS/BRAFV600Emut genotype compared to the MSS/BRAF wild-type (WT) genotype (16% vs. 42%, p=0.23). e. Disease-specific survival of adult onset-MSI genotype compared to early-age onset-MSI genotype in colorectal cancer patients. Both adult and early-age onset MSI were associated with favorable survivals, though adult-MSI genotype was associated with a more favorable 5-year disease-specific survival (93% vs. 65%, P=0.01).
Figure 1
Figure 1
Disease-specific survival according to age, microsatellite genotype and microsatellite genotype in relation to BRAF mutational status. a. Disease-specific survival of early-age onset colorectal cancer compared to adult onset colorectal cancer patients. 5-year disease-specific survival in the early-age onset group is worse compared to the adult onset group (48% vs. 78%, P<0.001). b. Disease-specific survival in adult-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (93% vs. 73%, P=0.006). c. Disease-specific survival in early-age onset colorectal cancer patients according to microsatellite instability (MSI) and microsatellite stability (MSS). MSI genotype was associated with a favorable 5-year disease-specific survival (65% vs. 39%, P=0.048). d. Disease-specific survival in early-age onset group with microsatellite stability (MSS) phenotype stratified according to BRAF mutational status. 5-year disease-specific survival trended worse in patients possessing the MSS/BRAFV600Emut genotype compared to the MSS/BRAF wild-type (WT) genotype (16% vs. 42%, p=0.23). e. Disease-specific survival of adult onset-MSI genotype compared to early-age onset-MSI genotype in colorectal cancer patients. Both adult and early-age onset MSI were associated with favorable survivals, though adult-MSI genotype was associated with a more favorable 5-year disease-specific survival (93% vs. 65%, P=0.01).

Similar articles

Cited by

References

    1. Surveillance, Epidemiology, and End Results program database. [Accessed June 30, 2015]; http://seer.cancer.gov/
    1. LaQuaglia MP, Heller G, Filippa DA, et al. Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J Pediatr Surg. 1992 Aug;27(8):1085–1089. discussion 1089-90. - PubMed
    1. Vastyan AM, Walker J, Pinter AB, Gerrard M, Kajtar P. Colorectal carcinoma in children and adolescents--a report of seven cases. Eur J Pediatr Surg. 2001 Oct;11(5):338–341. - PubMed
    1. Singh Y, Vaidya P, Hemandas AK, Singh KP, Khakurel M. Colorectal carcinoma in nepalese young adults: Presentation and outcome. Gan To Kagaku Ryoho. 2002 Feb;29(Suppl 1):223–229. - PubMed
    1. Hill DA, Furman WL, Billups CA, et al. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol. 2007 Dec 20;25(36):5808–5814. - PubMed

MeSH terms